VIA
TGTX icon

Virtus Investment Advisers’s TG Therapeutics TGTX Stock Holding History

Virtus Investment Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
23,483
-3,447
-13% -$141K 0.3% 158
2026
Q1 		$895K Buy
26,930
+5,131
+24% +$153K 0.25% 147
2025
Q4 		$650K Buy
21,799
+9,907
+83% +$324K 0.18% 204
2025
Q3 		$430K Hold
11,892
– – 0.12% 219
2025
Q2 		$428K Buy
11,892
+195
+2% +$7.26K 0.14% 214
2025
Q1 		$461K Buy
+11,697
New +$394K 0.13% 201

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Virtus Investment Advisers's TGTX Position: Q2 2026 in Review

Virtus Investment Advisers reduced its TG Therapeutics (TGTX) stake by 13% in Q2 2026, selling an estimated $141K and leaving 23,483 shares worth $1.29M. The position accounts for 0.3% of the portfolio, ranked #158.

Virtus Investment Advisers first reported a position in TGTX in Q1 2025 and has held it in 6 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Virtus Investment Advisers held 23,483 shares of TG Therapeutics worth $1.29M as of Q2 2026.
  • Virtus Investment Advisers sold 3,447 TG Therapeutics shares in Q2 2026, an estimated $141K.
  • TG Therapeutics made up 0.3% of Virtus Investment Advisers's portfolio in Q2 2026, its #158 holding.
  • Virtus Investment Advisers first reported a position in TG Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.